Drug intelligence / Profile preview

avastinib

Development stage: Preclinical
Lead developer: Genentech
Modality: Small Molecules
Administration: Intravenous

Overview

Avastinib is a drug being investigated as a maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). It is part of a mutation-based guided post-transplantation maintenance therapy regimen, as studied in the NCT06972641 clinical trial. Based on its '-tinib' suffix, it is likely a small molecule tyrosine kinase inhibitor, though its specific mechanism of action and target are not explicitly stated in the available context.

Beyond the preview

Go deeper on avastinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on avastinib.

Explore the full profile